Binance Pay Goes Live at PayPay Merchants in Japan 
RBA Hikes Interest Rate to 4.60% as Inflation Risks Rise 
CSL Partners With AWS to Bring AI Into Drug Research 
BlackRock Sees AI Agents Fueling New Crypto Demand 
Google Pays Publishers for AI Search Content in New Pilot 
Apple CEO John Ternus Plans Major Overhaul 
Lindt Slashes 2026 Sales Growth Forecast as European Demand Weakens 
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal 
Goldman Sachs Private Credit Fund Sees Redemptions Ease in Q3 
Nvidia China Chip Sales Report Sends Chinese Semiconductor Stocks Lower 
Gold Holds Near Seven-Week Low as Fed Rate Hike Bets Rise 
Gold Plunges 4% as Treasury Yields Surge and Fed Rate Hike Bets Rise 
HUTCHMED, AstraZeneca Seek FDA Approval for Lung Cancer Combo 
Dollar Eases Near Two-Month High as Yen Rebounds 
Goldman Sachs Eyes John Waldron as CEO Successor 
Australia Inflation Accelerates to 4% After RBA Rate Hike 
Add as a preferred source on Google
Unilever is looking to sell or de-emphasize its food & beverage units as it eyes the consumer healthcare division of GlaxoSmithKline, whose products include Advil pain reliever and Aquafresh and Sensodyne toothpaste.
The latest bid was reported at $68 billion, which would require Unilever to raise cash, which may prompt it to sell off its remaining food & beverage portfolio.
Unilever’s food & beverage products include Ben & Jerry’s ice cream and Hellman’s mayonnaise.
According to Unilever, its strategic direction lies in materially expanding its health, beauty, and hygiene businesses, which would require major acquisitions accompanied by the accelerated divestment of lower-growth brands and businesses.
Unilever had sold parts of its food and beverage businesses recently, including its spreads portfolio in 2017 and most of its tea business in 2020.
According to Unilever CEO Alan Jope, while its food and refreshments products are still profitable, its long-term growth profile has been below other parts of its portfolio.
